Correspondence 0001062993-23-014857 from ImmunoPrecise Antibodies Ltd. (IPA) (CIK 0001715925) (HYFT)
ImmunoPrecise Antibodies Ltd. (IPA) (CIK 0001715925)
Date: July 13, 2023 · CIK: 0001715925 · Accession: 0001062993-23-014857
AI Filing Summary & Sentiment
File numbers found in text: 333-273197
Letter
Re: Request for Acceleration - ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd.: CORRESP - Filed by newsfilecorp.com
July 13, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-3
(SEC File No. 333-273197)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, ImmunoPrecise Antibodies Ltd. (the "Company"), respectfully requests that the Commission accelerate the effectiveness of the above-referenced Registration Statement on Form F-3 (File No. 333-273197), and permit said Registration Statement to become effective at 4:00 p.m. (Eastern Time) on July 14, 2023, or as soon thereafter as practicable.
The Company hereby authorizes James Guttman, an attorney with our outside legal counsel, Dorsey & Whitney LLP, to orally modify or withdraw this request for acceleration.
Please contact James Guttman of Dorsey & Whitney LLP at (416) 367-7376 with any questions with respect to this request.
Sincerely,
ImmunoPrecise Antibodies Ltd.
Show Raw Text
CORRESP
1
filename1.htm
ImmunoPrecise Antibodies Ltd.: CORRESP - Filed by newsfilecorp.com
July 13, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Request for Acceleration - ImmunoPrecise Antibodies Ltd.
Registration Statement on Form F-3
(SEC File No. 333-273197)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, ImmunoPrecise Antibodies Ltd. (the "Company"), respectfully requests that the Commission accelerate the effectiveness of the above-referenced Registration Statement on Form F-3 (File No. 333-273197), and permit said Registration Statement to become effective at 4:00 p.m. (Eastern Time) on July 14, 2023, or as soon thereafter as practicable.
The Company hereby authorizes James Guttman, an attorney with our outside legal counsel, Dorsey & Whitney LLP, to orally modify or withdraw this request for acceleration.
Please contact James Guttman of Dorsey & Whitney LLP at (416) 367-7376 with any questions with respect to this request.
Sincerely,
ImmunoPrecise Antibodies Ltd.
/s/ Brad McConn
Brad McConn
Chief Financial Officer